Eradication of rat malignant gliomas by retroviral-mediated, in vivo delivery of the interleukin 4 gene.

Overexpression of interleukin 4 (IL-4) can impair the tumorigenicity of glioma cells, but direct evidence of its antitumor efficacy after in vivo gene transfer into malignant gliomas has not been provided. To test this, we first injected into the brain of Sprague Dawley rats a 1:1 mixture of C6 rat glioblastoma cells and psi2.L4SN20 or E86.L4SN50 retroviral producer cells (RPCs), secreting 20 and 50 ng of IL-4/5 x 10(5) cells/48 h, respectively. Twenty-seven and 56% of rats receiving injections with these low- or medium-level IL-4 RPCs, respectively, survived tumor injection, whereas control rats died in about 1 month. E86.L4SN50 RPCs coinjected with 9L gliosarcoma cells into syngeneic Fischer 344 rats yielded similar results. A novel IL-4 RPC clone expressing higher levels of IL-4, E86.L4SN200, coinjected with 9L cells increased to 75% the fraction of long-term survivors and induced tumor regression in 50% of rats when injected into established 9L gliosarcomas. Cured rats developed an immunological memory because they rejected a challenge of wild-type 9L cells into the contralateral hemisphere. Magnetic resonance imaging was used to monitor 9L and C6 gliomas and gave direct evidence for tumor rejection in treated rats. Immunohistology showed inflammatory infiltrates in IL-4-treated tumors in which CD8+ T lymphocytes were more abundant, although CD4+ T lymphocytes, B lymphocytes, and macrophages were also present. Overall, these findings suggest that IL-4 gene transfer is a new, promising approach for treating malignant gliomas.

[1]  J. Peterson,et al.  Inhibition of Angiogenesis by Interleukin 4 , 1998, The Journal of experimental medicine.

[2]  T. Blankenstein,et al.  Neutrophils but not eosinophils are involved in growth suppression of IL-4-secreting tumors. , 1998, Journal of immunology.

[3]  Z. Ram,et al.  Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells , 1997, Nature Medicine.

[4]  D. Bigner,et al.  Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion. , 1997, Neurosurgery.

[5]  S. Tseng,et al.  Induction of Antitumor Immunity by Intracerebrally Implanted Rat C6 Glioma Cells Genetically Engineered to Secrete Cytokines , 1997, Journal of immunotherapy.

[6]  P. Knopf,et al.  Growth of P511 mastocytoma cells in BALB/c mouse brain elicits CTL response without tumor elimination: a new tumor model for regional central nervous system immunity. , 1997, Journal of immunology.

[7]  I. Davis,et al.  The paracrine role of tumour‐derived mIL‐4 on tumour‐associated endothelium , 1997, International journal of cancer.

[8]  M. Colombo,et al.  Limited efficacy of the HSV-TK/GCV system for gene therapy of malignant gliomas and perspectives for the combined transduction of the interleukin-4 gene. , 1997, Human gene therapy.

[9]  R. Martuza,et al.  Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma. , 1997, Cancer gene therapy.

[10]  A. Aguzzi,et al.  Curing Rat Glioblastoma: Immunotherapy or Graft Rejection? , 1997, Science.

[11]  Erwin G. Van Meir,et al.  Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? , 1997, The Journal of clinical investigation.

[12]  G. Vogel.  The Pentagon Steps Up the Battle to Save Biodiversity , 1997, Science.

[13]  B. Groner,et al.  Retroviral targeted delivery. , 1996, Gene therapy.

[14]  M. Westphal,et al.  Adenovirus‐mediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivo , 1996, International journal of cancer.

[15]  B. Engelhardt,et al.  Lymphocyte Targeting of the Central Nervous System: A Review of Afferent and Efferent CNS‐Immune Pathways , 1996, Brain pathology.

[16]  H. Ishida,et al.  Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro. , 1995, Neurosurgery.

[17]  D. Silbergeld,et al.  Invading C6 glioma cells maintaining tumorigenicity. , 1995, Journal of neurosurgery.

[18]  Alexander Jw,et al.  Administration of intragraft interleukin-4 prolongs cardiac allograft survival in rats treated with donor-specific transfusion/cyclosporine. , 1995 .

[19]  Adriano Fontana,et al.  The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-β, T-cell apoptosis, and the immune privilege of the brain , 1995, Brain Research Reviews.

[20]  G. Barnett,et al.  Human astrocyte growth regulation: interleukin-4 sensitivity and receptor expression , 1995, Journal of Neuroimmunology.

[21]  G. Finocchiaro,et al.  The "bystander effect": association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice. , 1995, Human gene therapy.

[22]  E. Thiel,et al.  Recombinant human interleukin 4 has antiproliferative activity on human tumor cell lines derived from epithelial and nonepithelial histologies. , 1995, Cancer research.

[23]  E. Gilboa,et al.  RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma. , 1995, Cancer research.

[24]  T. Tamiya,et al.  Enhancement of interleukin-4-mediated tumor regression in athymic mice by in situ retroviral gene transfer. , 1995, Human gene therapy.

[25]  G. Butti,et al.  A short term analysis of the behaviour of conditionally immortalized neuronal progenitors and primary neuroepithelial cells implanted into the fetal rat brain. , 1994, Brain research. Developmental brain research.

[26]  P. Musiani,et al.  An efficient Th2-type memory follows CD8+ lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. , 1994, Journal of immunology.

[27]  I. Pastan,et al.  Human neurological cancer cells express interleukin‐4 (IL‐4) receptors which are targets for the toxic effects of IL4‐pseudomonas exotoxin chimeric protein , 1994, International journal of cancer.

[28]  Z. Ram,et al.  In vivo transfer of the human interleukin-2 gene: negative tumoricidal results in experimental brain tumors. , 1994, Journal of neurosurgery.

[29]  Nicolas de Tribolet,et al.  Recent advances in immunobiology of brain tumors , 1993, Journal of Neuro-Oncology.

[30]  R. Martuza,et al.  Treatment of glioma by engineered interleukin 4-secreting cells. , 1993, Cancer research.

[31]  Z. Ram,et al.  In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. , 1992, Science.

[32]  T. Roszman,et al.  Modulation of T-cell function by gliomas. , 1991, Immunology today.

[33]  P. Leder,et al.  Murine interleukin-4 displays potent anti-tumor activity in vivo , 1989, Cell.

[34]  T. Mosmann,et al.  Species-specificity of T cell stimulating activities of IL 2 and BSF-1 (IL 4): comparison of normal and recombinant, mouse and human IL 2 and BSF-1 (IL 4). , 1987, Journal of immunology.

[35]  W. Paul,et al.  Receptors for B-cell stimulatory factor-1 expressed on cells of haematopoietic lineage , 1987, Nature.

[36]  Robert E. Gentry,et al.  Immunobiology of primary intracranial tumors. , 1977, Journal of neurosurgery.

[37]  D. Bigner,et al.  Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients. , 1977, Journal of neurosurgery.

[38]  S. Brem,et al.  Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. , 1998, Journal of neurosurgery.

[39]  E. Chiocca,et al.  Effects on brain tumor cell proliferation by an adenovirus vector that bears the interleukin-4 gene. , 1998, Journal of neurovirology.

[40]  J. Markert,et al.  Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins , 1998, Gene Therapy.

[41]  M. Izquierdo,et al.  Long-term rat survival after malignant brain tumor regression by retroviral gene therapy. , 1995, Gene therapy.

[42]  J. Alexander,et al.  Administration of intragraft interleukin-4 prolongs cardiac allograft survival in rats treated with donor-specific transfusion/cyclosporine. , 1995, Transplantation.

[43]  Z. Ram,et al.  In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. , 1993, Cancer research.

[44]  P. Knopf,et al.  Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. , 1992, Immunology today.